Havemeyer Place LP Purchases New Holdings in BioNTech SE Sponsored ADR $BNTX

Havemeyer Place LP purchased a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 6,914 shares of the company’s stock, valued at approximately $658,000.

Several other institutional investors have also made changes to their positions in BNTX. Dodge & Cox boosted its stake in shares of BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after buying an additional 2,769,654 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after buying an additional 474,796 shares during the period. Bank of America Corp DE boosted its stake in shares of BioNTech by 344.4% in the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock valued at $56,544,000 after buying an additional 444,332 shares during the period. SG Americas Securities LLC boosted its stake in shares of BioNTech by 1,664.6% in the fourth quarter. SG Americas Securities LLC now owns 365,333 shares of the company’s stock valued at $34,780,000 after buying an additional 344,630 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of BioNTech by 910.3% in the third quarter. Millennium Management LLC now owns 246,327 shares of the company’s stock valued at $24,293,000 after buying an additional 276,727 shares during the period. 15.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wells Fargo & Company cut their price target on BioNTech from $150.00 to $140.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Citigroup cut their price target on BioNTech from $145.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Morgan Stanley boosted their price objective on shares of BioNTech from $125.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Raymond James Financial restated an “outperform” rating on shares of BioNTech in a research report on Tuesday, March 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $129.56.

BioNTech Stock Down 2.9%

Shares of BNTX opened at $85.50 on Tuesday. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The company has a market cap of $21.62 billion, a P/E ratio of -14.54 and a beta of 1.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.80 and a quick ratio of 8.74. The firm has a 50 day simple moving average of $94.50 and a two-hundred day simple moving average of $98.75.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The firm had revenue of $1.06 billion for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. Research analysts forecast that BioNTech SE Sponsored ADR will post -4.66 EPS for the current fiscal year.

BioNTech declared that its Board of Directors has initiated a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

Insider Activity

In other news, COO Sierk Poetting sold 50,000 shares of the company’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the completion of the transaction, the chief operating officer directly owned 399,387 shares in the company, valued at approximately $44,156,226.72. This represents a 11.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.20% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.